Antimicrobial resistance is a global health crisis and carbapenem-resistant Klebsiella pneumoniae(CRKp)is listed as one of the top high-priority pathogens by the World Health Organization.Meanwhile,hypervirulent K.pne...Antimicrobial resistance is a global health crisis and carbapenem-resistant Klebsiella pneumoniae(CRKp)is listed as one of the top high-priority pathogens by the World Health Organization.Meanwhile,hypervirulent K.pneumoniae(hvKp)causes severe community-associated infections,such as liver abscesses and meningitis,in otherwise healthy individuals.Both CRKp and hvKp infections are associated with high mortality rates.The convergence of carbapenem resistance and hypervirulence within a single bacterial strain may lead to significantly more severe clinical outcomes.展开更多
Recent advancements in cancer therapeutics,including targeted therapies and immunotherapies,have significantly improved treatment outcomes but remain limited by challenges such as off-target toxicity,poor penetration ...Recent advancements in cancer therapeutics,including targeted therapies and immunotherapies,have significantly improved treatment outcomes but remain limited by challenges such as off-target toxicity,poor penetration into deep tumor tissues,and the emergence of drug resistance.Engineered bacteria-based cancer therapies present a novel and versatile approach to address these limitations.Leveraging their ability to selectively colonize tumor microenvironments,bacteria can elicit antitumor immune responses and serve as platforms for the localized delivery of therapeutic agents.Through genetic engineering and synthetic biology,bacteria can be programmed to produce anticancer payloads tailored to clinical needs.This review highlights recent progress in the design and application of engineered bacteria for cancer therapy,emphasizing innovative strategies to enhance therapeutic delivery and efficacy.In addition,we discuss the integration of bacteria-based approaches with conventional therapies to overcome intratumor heterogeneity and improve treatment outcomes.Finally,we discuss insights from past and ongoing clinical trials of tumor-targeting bacteria,alongside challenges that must be surmounted to realize their full therapeutic promise.展开更多
End-stage liver disease(ESLD)is a life-threatening clinical syndrome that markedly increases mortality in patients with infections.In patients with ESLD,infections can induce or aggravate the occurrence of liver decom...End-stage liver disease(ESLD)is a life-threatening clinical syndrome that markedly increases mortality in patients with infections.In patients with ESLD,infections can induce or aggravate the occurrence of liver decompensation.Consequently,infections are among the most common complications of disease progression.There is a lack of working procedure for early diagnosis and appropriate management for patients with ESLD complicated by infections as well as local and international guidelines or consensus.This consensus assembled up-to-date knowledge and experience across Chinese colleagues,providing data on principles as well as working procedures for the diagnosis and treatment of patients with ESLD complicated by infections.展开更多
基金supported by the National Natural Science Foundation of China(grant numbers 81991531 to M.W.,82102440 to J.J.,and 32400149 to J.Z.).
文摘Antimicrobial resistance is a global health crisis and carbapenem-resistant Klebsiella pneumoniae(CRKp)is listed as one of the top high-priority pathogens by the World Health Organization.Meanwhile,hypervirulent K.pneumoniae(hvKp)causes severe community-associated infections,such as liver abscesses and meningitis,in otherwise healthy individuals.Both CRKp and hvKp infections are associated with high mortality rates.The convergence of carbapenem resistance and hypervirulence within a single bacterial strain may lead to significantly more severe clinical outcomes.
文摘Recent advancements in cancer therapeutics,including targeted therapies and immunotherapies,have significantly improved treatment outcomes but remain limited by challenges such as off-target toxicity,poor penetration into deep tumor tissues,and the emergence of drug resistance.Engineered bacteria-based cancer therapies present a novel and versatile approach to address these limitations.Leveraging their ability to selectively colonize tumor microenvironments,bacteria can elicit antitumor immune responses and serve as platforms for the localized delivery of therapeutic agents.Through genetic engineering and synthetic biology,bacteria can be programmed to produce anticancer payloads tailored to clinical needs.This review highlights recent progress in the design and application of engineered bacteria for cancer therapy,emphasizing innovative strategies to enhance therapeutic delivery and efficacy.In addition,we discuss the integration of bacteria-based approaches with conventional therapies to overcome intratumor heterogeneity and improve treatment outcomes.Finally,we discuss insights from past and ongoing clinical trials of tumor-targeting bacteria,alongside challenges that must be surmounted to realize their full therapeutic promise.
文摘End-stage liver disease(ESLD)is a life-threatening clinical syndrome that markedly increases mortality in patients with infections.In patients with ESLD,infections can induce or aggravate the occurrence of liver decompensation.Consequently,infections are among the most common complications of disease progression.There is a lack of working procedure for early diagnosis and appropriate management for patients with ESLD complicated by infections as well as local and international guidelines or consensus.This consensus assembled up-to-date knowledge and experience across Chinese colleagues,providing data on principles as well as working procedures for the diagnosis and treatment of patients with ESLD complicated by infections.
